ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BRUKINSA® (zanubrutinib) de BeiGene recibe una opinión positiva del CHMP para el tratamiento de adultos con macroglobulinemia de Waldenström

September 17, 2021 GMT

BASILEA, Suiza, CAMBRIDGE, Massachusetts (EE. UU.) y PEKÍN, China--(BUSINESS WIRE)--sep. 17, 2021--

CONTACT: Contacto con inversores

Gabrielle Zhou

+86 10-5895-8058 or +1 857-302-5189

ir@beigene.com

Contacto con los medios de comunicación

Liza Heapes or Vivian Ni

+1 857-302-5663 or +1 857-302-7596

media@beigene.com

KEYWORD: SWITZERLAND CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC EUROPE MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: BeiGene

Copyright Business Wire 2021.

PUB: 09/17/2021 08:00 AM/DISC: 09/17/2021 08:02 AM

http://www.businesswire.com/news/home/20210917005239/es